Guobang Pharma Ltd Market Cap ($1.80 Billion)
Market Cap & Net Worth: Guobang Pharma Ltd (605507)
Guobang Pharma Ltd market cap. Guobang Pharma Ltd (SHG:605507) has a market capitalization of $1.80 Billion (CN¥12.29 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #6303 globally and #1215 in its home market, demonstrating a 8.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guobang Pharma Ltd's stock price CN¥15.71 by its total outstanding shares 782352900 (782.35 Million). Also see Guobang Pharma Ltd (605507) cash conversion ratio for how efficiently the company converts equity into cash flow.
Guobang Pharma Ltd Market Cap History (2021–2026)
Guobang Pharma Ltd market cap history from 2021 to 2026. Data shows change from $3.13 Billion to $1.80 Billion (-17.66% CAGR). Check today's stock price for Guobang Pharma Ltd for real-time trading data and today's change.
Guobang Pharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guobang Pharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 605507 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.47x
Guobang Pharma Ltd's market cap is 0.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.46x
Guobang Pharma Ltd's market cap is 3.46 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $3.13 Billion | $4.51 Billion | $706.03 Million | 0.69x | 4.43x |
| 2022 | $2.90 Billion | $5.72 Billion | $920.90 Million | 0.51x | 3.15x |
| 2023 | $1.98 Billion | $5.35 Billion | $612.46 Million | 0.37x | 3.22x |
| 2024 | $2.38 Billion | $5.89 Billion | $781.60 Million | 0.40x | 3.05x |
| 2025 | $2.84 Billion | $6.01 Billion | $820.82 Million | 0.47x | 3.46x |
Competitor Companies of 605507 by Market Capitalization
Companies near Guobang Pharma Ltd in the global market cap rankings as of November 8, 2026. Also see 605507 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Guobang Pharma Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Guobang Pharma Ltd (2021–2026)
Market capitalization of Guobang Pharma Ltd from 2021 to today. Between 2021 and today, Guobang Pharma Ltd's market cap moved from $3.13 Billion to $ 1.80 Billion, with a yearly change of -17.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.80 Billion | -36.65% |
| 2025 | CN¥2.84 Billion | +19.06% |
| 2024 | CN¥2.38 Billion | +20.74% |
| 2023 | CN¥1.98 Billion | -31.87% |
| 2022 | CN¥2.90 Billion | -7.40% |
| 2021 | CN¥3.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Guobang Pharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.80 Billion USD |
| MoneyControl | $1.80 Billion USD |
| MarketWatch | $1.80 Billion USD |
| marketcap.company | $1.80 Billion USD |
| Reuters | $1.80 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives.… Read more